0001193125-21-251474.txt : 20210921 0001193125-21-251474.hdr.sgml : 20210921 20210819160200 ACCESSION NUMBER: 0001193125-21-251474 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 CORRESP 1 filename1.htm CORRESP

INOZYME PHARMA, INC.

321 Summer Street, Suite 400

Boston, MA 02210

August 19, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Inozyme Pharma, Inc.

Registration Statement on Form S-3

File No. 333-258702

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-258702), so that it may become effective at 4:30 p.m. Eastern time on August 23, 2021, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

 

Very truly yours,
INOZYME PHARMA, INC.
By:  

/s/ Axel Bolte

Name:   Axel Bolte
Title:   President and Chief Executive Officer

 

cc:

Brian A. Johnson

Wilmer Cutler Pickering Hale and Dorr LLP